The Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement

Simple item page
dc.contributor.authorChopra H.K.
dc.contributor.authorWander G.S.
dc.contributor.authorPonde C.K.
dc.contributor.authorNanda N.C.
dc.contributor.authorKhullar D.
dc.contributor.authorVenugopal K.
dc.contributor.authorRay S.
dc.contributor.authorNair T.
dc.contributor.authorRana D.S.
dc.contributor.authorKher V.
dc.contributor.authorSawhney J.P.S.
dc.contributor.authorKasliwal R.R.
dc.contributor.authorAbdullakutty J.
dc.contributor.authorChakraborty R.
dc.contributor.authorChandra P.
dc.contributor.authorBansal S.
dc.contributor.authorKumar V.
dc.contributor.authorPancholia A.K.
dc.contributor.authorKapoor A.
dc.contributor.authorPrakash S.
dc.contributor.authorSaxena A.
dc.contributor.authorRastogi V.
dc.contributor.authorSharma V.
dc.contributor.authorArora Y.K.
dc.contributor.authorDasbiswas A.
dc.contributor.authorBhargava M.
dc.contributor.authorJaswal A.
dc.contributor.authorBhargava K.
dc.contributor.authorBhatia M.
dc.contributor.authorOmar A.K.
dc.contributor.authorKhanna N.N.
dc.contributor.authorPassey R.
dc.contributor.authorBhalla D.
dc.contributor.authorVijayalakshmi I.B.
dc.contributor.authorBhalla A.K.
dc.contributor.authorMoorthy A.
dc.contributor.authorIsser H.S.
dc.contributor.authorMishra S.S.
dc.contributor.authorRoutray S.
dc.contributor.authorTandon V.
dc.contributor.authorSinha A.
dc.contributor.authorBansal M.
dc.contributor.authorJain P.
dc.contributor.authorHotchandani R.
dc.contributor.authorJain D.
dc.contributor.authorKatyal V.K.
dc.contributor.authorGulati S.
dc.contributor.authorTandon R.
dc.contributor.authorJaggi S.
dc.contributor.authorSehgal B.
dc.contributor.authorGupta V.
dc.contributor.authorMehrotra R.
dc.contributor.authorKrishnamani N.C.
dc.contributor.authorPathak S.N.
dc.contributor.authorYadav M.S.
dc.contributor.authorChawla R.
dc.contributor.authorShastry N.R.
dc.contributor.authorChatterjee N.
dc.contributor.authorSamajdar S.S.
dc.contributor.authorPal J.
dc.contributor.authorTiwaskar M.
dc.date.accessioned2025-01-13T07:09:02Z
dc.date.available2025-01-13T07:09:02Z
dc.date.issued2024
dc.description.abstractThe rapidly increasing burden of hypertension is responsible for premature deaths from cardiovascular disease (CVD), renal disease, and stroke, with a tremendous public health and financial burden. Hypertension detection, treatment, and control vary worldwide; it is still low, particularly in low- and middle-income countries (LMICs). High blood pressure (BP) and CVD risk have a strong, linear, and independent association. They contribute to alarming numbers of all-cause and CVD deaths. A major culprit for increased hypertension is sympathetic activity, and further complications of hypertension are heart failure, ischemic heart disease (IHD), stroke, and renal failure. Now, antihypertensive interventions have emerged as a global public health priority to reduce BP-related morbidity and mortality. Calcium channel blockers (CCB) are highly effective vasodilators. and the most common drugs used for managing hypertension and CVD. Cilnidipine, with both L- and N-type calcium channel blocking activity, is a promising 4th generation CCB. It causes vasodilation via L-type calcium channel blockade and inhibits the sympathetic nervous system (SNS) via N-type calcium channel blockade. Cilnidipine, which acts as a dual L/N-type CCB, is linked to a reduced occurrence of pedal edema compared to amlodipine, which solely blocks L-type calcium channels. The antihypertensive properties of cilnidipine are very substantial, with low BP variability and long-acting properties. It is beneficial for hypertensive patients to deal with morning hypertension and for patients with abnormal nocturnal BP due to exaggerated sympathetic nerve activation. Besides its BP-lowering effect, it also exhibits organ protection via sympathetic nerve inhibition and renin�angiotensin�aldosterone system inhibition; it controls heart rate and proteinuria. Reno-protective, neuroprotective, and cardioprotective effects of cilnidipine have been well-documented and demonstrated. � 2024 Journal of Association of Physicians of India. All rights reserved.
dc.identifier.doi10.59556/japi.71.0400
dc.identifier.issn45772
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/3490
dc.language.isoen
dc.publisherJournal of Association of Physicians of India
dc.titleThe Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement
dc.typeArticle
journal.titleJournal of Association of Physicians of India
journalvolume.identifier.volume72

Files

Collections

2024